Kennedy Capital Management’s Exagen XGN Stock Holding History

Kennedy Capital Management’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.26M	Sell	485,048 -8,612	-2%	-$32.4K	0.04%	437
2026 Q1	$1.48M	Buy	493,660 +13,631	+3%	+$52.7K	0.03%	444
2025 Q4	$2.92M	Sell	480,029 -71,819	-13%	-$654K	0.06%	385
2025 Q3	$6.06M	Buy	551,848 +241,127	+78%	+$2.14M	0.13%	257
2025 Q2	$2.17M	Buy	310,721 +15,568	+5%	+$94.6K	0.05%	433
2025 Q1	$1.06M	Buy	295,153 +110,680	+60%	+$418K	0.03%	508
2024 Q4	$756K	Buy	184,473 +14,920	+9%	+$53.8K	0.02%	616
2024 Q3	$524K	Buy	169,553 +93,040	+122%	+$241K	0.01%	634
2024 Q2	$139K	Buy	+76,513	New	+$130K	﹤0.01%	689

Other funds holding XGN

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

MBAM

Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Kennedy Capital Management's XGN Position: Q2 2026 in Review

Kennedy Capital Management reduced its Exagen (XGN) stake by 1.7% in Q2 2026, selling an estimated $32.4K and leaving 485,048 shares worth $2.26M. The position accounts for 0.04% of the portfolio, ranked #437.

Kennedy Capital Management first reported a position in XGN in Q2 2024 and has held it in 9 quarters since. The position peaked at $6.06M in Q3 2025. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

Kennedy Capital Management held 485,048 shares of Exagen worth $2.26M as of Q2 2026.
Kennedy Capital Management sold 8,612 Exagen shares in Q2 2026, an estimated $32.4K.
Exagen made up 0.04% of Kennedy Capital Management's portfolio in Q2 2026, its #437 holding.
Kennedy Capital Management first reported a position in Exagen in Q2 2024 and has held it in 9 quarters since.
Kennedy Capital Management's Exagen position peaked at $6.06M in Q3 2025.
57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.